Early Detection and remediation
Decoding Dementia and Diabetes
About Ascento-CDA
Our Mission
Ascento turns invisible early biology into actionable intelligence—creating measurable economic value for insurers, new opportunities for Health Providers, strategic value for Pharma, and better outcomes for patients years before traditional markers detect disease
By shifting detection into the pre-symptomatic “Golden Hour”, we deliver clinical impact and financial returns at scale.
Our Technology
Our proprietary platform, IICM™ (Inflammatory, Immunologic & Cognitive Mapping), is a clinician-facing analytics platform that integrates retinal imaging signals, inflammatory biomarker data, and cognitive assessment information to support clinician-led insights into cognitive and metabolic health.
By bringing together data streams that are typically reviewed in isolation, IICM™ helps surface patterns and relationships that may not be apparent through traditional tools alone. Advanced analytics and machine learning are used to organize, contextualize, and visualize complex clinical information, supporting clinician-led interpretation and discussion.
IICM™ is designed to support preventive care initiatives, value-based care programs, and population health strategies by enabling earlier engagement, improved care coordination, and a more integrated understanding of patient data.First publication can found here:
https://www.medrxiv.org/content/10.1101/2025.10.14.25337174v1.full.pdf+html
The Clinical Aspects
Our proprietary platform, IICM™ (Inflammatory, Immunologic & Cognitive Mapping), helps clinicians detect the active drivers of cognitive decline and diabetes at the earliest stages — often before symptoms appear.
By combining cognitive testing to identify subtle brain deficits, biomarker analysis to detect inflammatory patterns, and AI-driven mapping to correlate findings, IICM™ reveals risks that standard screening overlooks.
This allows physicians to reclassify patients more accurately, identify which underlying conditions may be accelerating decline, and make timely, targeted interventions that improve care quality and long-term outcomes.
Impact!
For Patients
IICM™ enables detection of cognitive decline and diabetes years earlier than conventional methods. By identifying risks and underlying conditions in the pre-symptomatic “Golden Hour,” patients gain access to timely interventions that can slow or prevent progression.
For Providers
Accurate risk reclassification creates opportunities for earlier-stage patient management and proactive interventions. This drives stronger engagement, supports chronic care programs, and ensures more effective use of medical resources.
For Insurers, Payviders and Pharma
Earlier detection delivers significant and measurable savings by reducing late-stage treatment costs, avoiding preventable hospitalizations, and improving performance on key quality metrics.